| Detected | Trial | Change |
|---|---|---|
| 2026-06-05 | NCT05669339 AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma |
date change Primary completion pushed: 2026-04 -> 2027-04 |
| 2026-06-05 | NCT05669339 AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma |
date change Completion pushed: 2026-04 -> 2027-04 |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT07463651 | MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib | Acute Myeloid Leukemia (AML) | Recruiting |
| NCT03298451 | Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced… | Hepatocellular Carcinoma | Active, Not Recruiting |
| NCT04039607 | A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced… | Hepatocellular Carcinoma | Active, Not Recruiting |
| NCT03017326 | Paediatric Hepatic International Tumour Trial | Hepatoblastoma | Active, Not Recruiting |
| NCT04770896 | A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone… | Unresectable Hepatocellular Carcinoma | Active, Not Recruiting |
| Phase 2 | |||
| NCT06309485 | Phase 2 Study of WGI-0301 for Advanced HCC | Advanced Hepatocellular Carcinoma (HCC) | Recruiting |
| NCT02559778 | Pediatric Precision Laboratory Advanced Neuroblastoma Therapy | Neuroblastoma | Recruiting |
| NCT05669339 | AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma | Hepatocellular Carcinoma | Recruiting |
| NCT02143726 | Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced… | Refractory Hurthle Cell Thyroid Cancer | Active, Not Recruiting |
| NCT06227221 | Efficacy and Safety of Sorafenib in New-Onset Type 1 Diabetes Mellitus | Type 1 Diabetes | Not Yet Recruiting |
| NCT01946529 | Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small… | Desmoplastic Small Round Cell Tumor | Active, Not Recruiting |
| NCT03164057 | A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia | Acute Myeloid Leukemia | Active, Not Recruiting |
| NCT01871766 | Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low… | Rhabdomyosarcoma | Active, Not Recruiting |
| NCT00265798 | Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That… | Gastrointestinal Stromal Tumor | Active, Not Recruiting |
| NCT01840592 | Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With… | Hepatocellular Carcinoma | Active, Not Recruiting |
| Phase 1/2 | |||
| NCT05468359 | Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in… | Refractory Solid Tumor | Recruiting |
| NCT03247088 | Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory… | Recurrent Acute Myeloid Leukemia | Active, Not Recruiting |
| Phase 1 | |||
| NCT02298348 | Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory… | Neuroblastoma | Active, Not Recruiting |
| NCT01303341 | Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or… | Advanced Malignant Solid Neoplasm | Active, Not Recruiting |
| NCT01861314 | Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid… | Acute Myeloid Leukemia | Active, Not Recruiting |
| NCT03132454 | Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With… | Recurrent Acute Lymphoblastic Leukemia | Active, Not Recruiting |
| NCT01187199 | Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2)… | Advanced Cancer | Active, Not Recruiting |
| Not specified | |||
| NCT02185560 | Prospective, Non-interventional, Post-authorization Safety Study That Includes All… | Thyroid Carcinoma | Active, Not Recruiting |